• Intervacc submitted a Type II variation to the EMA for Strangvac, seeking to extend the vaccine’s stated duration of immunity to 12 months.
• The filing is backed by data showing protective antibody levels persist for 12 months following completion of the primary vaccination course.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intervacc AB published the original content used to generate this news brief via Cision (Ref. ID: 20260729:BIT:2829:0) on July 30, 2026, and is solely responsible for the information contained therein.